

FORM PTO-1390 (REV. 10-2003)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 96700/905	
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>10/501628</b>	
INTERNATIONAL APPLICATION NO. PCT/US03/01149		INTERNATIONAL FILING DATE January 15, 2003		PRIORITY DATE CLAIMED January 17, 2002	
TITLE OF INVENTION <b>MUTATIONS CAUSED BY ACTIVATION-INDUCED CYTIDINE DEAMINASE</b>					
APPLICANT(S) FOR DO/EO/US Alberto Martin and Matthew D. Scharff					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> <li>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))           <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>					
<b>Items 11 to 20 below concern document(s) or information included:</b>					
<ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input type="checkbox"/> A preliminary amendment.</li> <li>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</li> <li>15. <input type="checkbox"/> A substitute specification.</li> <li>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</li> <li>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.</li> <li>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li>20. <input checked="" type="checkbox"/> Other items or information: transmittal cover letter; AR&amp;E check for \$430.00; and return receipt postcard.</li> </ol>					

U.S. APPLICATION NO. <b>10/501628</b> <small>(If known, see 37 CFR 1.5)</small>		INTERNATIONAL APPLICATION NO. PCT/US03/01149		ATTORNEY'S DOCKET NUMBER 96700/905	
--	--	---	--	---------------------------------------	--

21. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO . . . . . <b>\$1080.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO . . . . . <b>\$920.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO . . . . . <b>\$770.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) . . . . . <b>\$730.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) . . . . . <b>\$100.00</b> <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>CALCULATIONS PTO USE ONLY</b>	
				\$ 730.00	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	- 20 =		x <b>\$18.00</b>		
Independent claims	- 3 =		x <b>\$86.00</b>		
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ <b>\$290.00</b>	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 860.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ 430.00	
<b>SUBTOTAL =</b>				\$ 430.00	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
<b>TOTAL NATIONAL FEE =</b>				\$ 430.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +				\$	
<b>TOTAL FEES ENCLOSED =</b>				\$ 430.00	
				Amount to be refunded:	\$
				<b>charged:</b>	\$

a. ☒ A check in the amount of \$ 430.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
 A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required <sup>to prevent abandonment,</sup> or credit any  
 overpayment to Deposit Account No. 01-1785. A duplicate copy of this sheet is enclosed.


d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card  
 information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a)  
 or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Craig J. Arnold, Esq.  
 Amster, Rothstein & Ebenstein LLP  
 90 Park Avenue  
 New York, NY 10016

  
 SIGNATURE  
 Elie H. Gendloff  
 NAME  
44,704  
 REGISTRATION NUMBER

**AMSTER  
ROTHSTEIN  
& EBENSTEIN LLP**

*Intellectual Property Law*

90 Park Avenue  
New York NY 10016

Main 212 336 8000

Fax 212 336 8001

Web [www.arelaw.com](http://www.arelaw.com)

*Partners*  
Morton Amster  
Jesse Rothstein (1934 - 2003)  
Daniel Ebenstein  
Philip H. Gottfried  
Michael J. Berger  
Neil M. Zipkin  
Anthony F. Lo Cicero  
Kenneth P. George  
Abraham Kasdan, Ph.D.  
Ira E. Silfin  
Chester Rothstein  
Craig J. Arnold  
Kenneth M. Bernstein

*Senior Counsel*  
Charles R. Macedo  
Mark J. Rosenberg  
Nancy M. Dodderidge

*Of Counsel*  
Jerry D. Dainow

*Associates*  
Neal L. Rosenberg  
Patrick Boland\*  
Trebzor Lloyd  
Joseph M. Casino  
John S. Economou

**DT03 Rec'd PCT/PTO 15 JUL 2004**

Michael V. Solomita  
Holly Pekowsky  
Michael P. Kenney  
Marion P. Metelski  
Max Vern  
Dana R. Metes  
Karl J. Kolbinger  
Brian A. Comack  
Richard S. Mandaro  
Marc J. Jason  
Elie H. Gendloff, Ph.D.  
David Mitnick  
Charles W. Rath  
David A. Boag

Karen J. Bernstein  
Matthieu Hausig  
Jung S. Hahn  
Reiko Kaji  
Alan D. Miller, Ph.D.  
Hsin-Hsin (Ginger) Liu  
John A. Lepore\*  
Norajean McCaffrey

\*Not admitted in New York

**10/501628**

July 15, 2004


Elie H. Gendloff, Ph.D., Esq.

Direct 212 336 8108

E-mail [egendlof@arelaw.com](mailto:egendlof@arelaw.com)

Via Express Mail

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

"Express Mail" mailing label No.	EL 996361569 US
Date of Deposit:	July 15, 2004
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Elie H. Gendloff
Signature:	

Re: National Stage Entry of PCT Application PCT/US03/01149  
Filed January 15, 2003 (International Filing Date)  
Title: MUTATIONS CAUSED BY ACTIVATION-INDUCED  
CYTIDINE DEAMINASE  
Inventor: Alberto Martin and Matthew D. Scharff  
Our File: 96700/905

Sir:

Enclosed please find the following documents for filing in connection with the above-identified application in the name of Albert Martin and Matthew D. Scharff, entitled MUTATIONS CAUSED BY ACTIVATION-INDUCED CYTIDINE DEAMINASE:

1. Transmittal Letter ... Form PTO-1390 (2 pages and 1 duplicate page of fee sheet, as required);
2. Copy of the International Application PCT/US03/01149, published under WO 03/061363;
3. Amster, Rothstein & Ebenstein LLP check in the amount of \$430.00 to cover the National Stage filing fees (claiming small entity status); and
4. Return receipt postcard.

10/501628

DT04 Rec'd PCT/PTO 1-5 JUL 2004  
July 15, 2004

Commissioner for Patents  
Alexandria, VA 22313-1450  
Mail Stop PCT

-2-


Please acknowledge receipt of the enclosed documents by stamping the enclosed postcard and returning same.

The Commissioner is hereby authorized to charge to Deposit Account 01-1785 any additional fees which may be required to prevent abandonment of this application.

Respectfully submitted,

Amster, Rothstein & Ebenstein LLP  
Attorneys for Applicants  
90 Park Avenue  
New York, NY 10016  
212 336 8000

Dated: New York, New York  
July 15, 2004

By:   
Elie Gendloff  
Registration No. 44,704